ResMed Inc. (RSMDF) Stock Price & Analysis
ResMed Inc. (RSMDF) — price $24.07 (0.00%), as of the Nov 19, 2026 trading session; market cap $33.9B.
Educational signal · not a buy or sell recommendation · How to read this
ResMed Inc. · RSMDF · Healthcare · Medical - Instruments & Supplies
ResMed Inc. engages in the digital health and cloud-connected medical devices business in the United States and internationally. It operates in two segments, Sleep and Breathing Health, and Residential Care Software.
Price as of Nov 19, 2026
Key Statistics
Not scored: MoonshotScore covers actively traded US operating companies, not funds, preferred shares, warrants or thinly traded stocks.
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $24.07 | |
| Change on the day | 0.00% | |
| 52-week range | $11.85–$28.25 | |
| Market capitalisation | $33.9B | — |
| Price / earnings (trailing) | 21.60 | |
| Shares traded on the day | 400 | |
| Beta (volatility vs the S&P 500) | 0.76 |
Price & events
Point at or tab to any week for its close.
Other perspectives
Council score for ResMed (RSMDF): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Legends Council
1 lens, 1 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Nov 19, 2026
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
Readings on this page are from Nov 20, 2026, except a card that shows its own read date.
What is ResMed (RSMDF), and what does it report?
Short answer
ResMed Inc. engages in the digital health and cloud-connected medical devices business in the United States and internationally. It operates in two segments, Sleep and Breathing Health, and Residential Care Software. Healthcare / Medical Instruments & Supplies Headquarters: 9001 Spectrum Center Boulevard, San Diego, CA, 92123, United States. It employs 11,370 people. In Q1 FY2027 it reported revenue of $1.41B and net income of $418M. The market values it at $33.9B.
What do the latest results show for ResMed (RSMDF)?
Short answer · as of
The most recent reported quarter, Q1 FY2027, carried revenue of $1.41B. Against analyst estimates the company has EPS beat 7 of the last 8 reports.
Where is operating spending going?
Revenue alongside research and development, selling, general and administrative expenses, and the FMP standardized operating result.
| Period end | Revenue | R&D | SG&A | FMP standardized operating result |
|---|---|---|---|---|
| Sep 30, 2026 | Not available | Not available | Not available | Not available |
| Jun 30, 2026 | Not available | Not available | Not available | Not available |
| Mar 31, 2026 | Not available | Not available | Not available | Not available |
| Dec 31, 2025 | Not available | Not available | Not available | Not available |
How to read these figures
Amounts are in US dollars. The operating result is Financial Modeling Prep’s standardized figure, so it can differ from the operating line in the company’s filing. It is not net income or cash flow.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q1 FY2027 | $1.41B | $418M | $2.92 (diluted) |
| Q4 FY2026 | $1.46B | $383M | $2.64 (diluted) |
| Q3 FY2026 | $1.43B | $399M | $2.71 (diluted) |
| Q2 FY2026 | $1.42B | $393M | $2.68 (diluted) |
What are the financial strengths and risks for ResMed (RSMDF)?
Short answer · as of
Cash and short-term investments were $0.00 at the Sep 30, 2026 balance-sheet date. This figure does not establish a cash runway. The distress and quality screens read Altman Z 12.50 · Piotroski F 6. Trailing ratios: ROE 25.1% · ROA 19.4% · current ratio 2.65 · earnings yield 4.6% · free-cash-flow yield 4.7%.
The records behind this page
Insider activity
Form 4 records via FMP · Of the newest 60 records, those within the last 180 days, newest dated Nov 11, 2026
- Transactions
- 38
- Identified insiders
- 7
- Purchases
- 0
- Sales
- 9
- Other transactions
- 29
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held RSMDF in their latest 13F filing, and what they did against the filing before it.
None of the 16 tracked investors reported RSMDF in their latest 13F filing.
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
Common Questions About RSMDF (Healthcare)
These answers are editorial: 1 of these 8 answers is drawn from the RSMDF research dossier (written Jun 15, 2026 by gemini-2.5-flash); the other 7 are question templates that restate figures shown above. Figures in this section are not part of the source register.
Is RSMDF a good stock to buy?
Stock Expert AI does not rate RSMDF buy, sell or hold. ResMed Inc. has no MoonshotScore yet; read the financial checkup, analyst consensus and risks directly. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.
What is the RSMDF stock price today?
The last price recorded for ResMed Inc. (RSMDF), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What are the unique considerations for investors in ResMed Inc. given its OTC listing?
Investing in ResMed Inc. (RSMDF) on the OTC market, particularly in the 'OTC Other' tier, presents unique considerations compared to stocks on major exchanges.
What are the key factors to evaluate for RSMDF?
Evaluate RSMDF on fundamentals, analyst consensus, and risk factors. To weigh it, start with the trailing P/E under Price & valuation on this page. This is an ongoing market trend with long-term implications for demand. Not financial advice.
How frequently does RSMDF data refresh on this page?
RSMDF's price is the last quote we recorded, from the Nov 19, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.
What has driven RSMDF's recent stock price performance?
ResMed Inc. (RSMDF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Leading global market position in sleep and respiratory care devices. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider RSMDF overvalued or undervalued right now?
The trailing P/E of ResMed Inc. (RSMDF) is listed under Price & valuation on this page. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research RSMDF before investing?
Before investing in ResMed Inc. (RSMDF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Machine-generated analysis by Stock Expert AI — model gemini-2.5-flash, generated Jun 15, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 24 figures on this page — 20 from Financial Modeling Prep (FMP) and 4 with no recorded source. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com